Merck announces an investment of €250 million in new facility in Switzerland

Merck, a science and technology company, has announced an investment of €250 million in a new facility in Corsier-sur-Vevey, Switzerland. The facility – Merck Biotech Development Centre – is dedicated to biotech development and manufacturing for clinical studies.

This investment will help to sustainably secure capacity and high agility to deliver clinical trial material in a cost-effective way, contribute to accelerated development timelines of new biological entities, and address the increasing manufacturing complexity of the next generations of biotech compounds, the company said in a statement.

“This investment in the Merck Biotech Development Center reflects our commitment to speed up the availability of new medicines for patients in need, and confirms the importance of Switzerland as our prime hub for the manufacturing of biotech medicines,” said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck, at the ground-breaking ceremony for the new facility held today.